Equities researchers at StockNews.com initiated coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) in a research report issued on Saturday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Trading Up 2.1 %
NASDAQ:TTNP opened at $6.35 on Friday. Titan Pharmaceuticals has a 52 week low of $4.24 and a 52 week high of $13.97. The firm has a 50-day moving average price of $6.18 and a two-hundred day moving average price of $6.72.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last posted its quarterly earnings data on Wednesday, May 15th. The specialty pharmaceutical company reported ($1.24) EPS for the quarter.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Featured Articles
- Five stocks we like better than Titan Pharmaceuticals
- Quiet Period Expirations Explained
- Why This AI Stock is Rising Despite Tech Sell-Off
- Low PE Growth Stocks: Unlocking Investment Opportunities
- MarketBeat Week in Review – 7/15 – 7/19
- 3 Healthcare Dividend Stocks to Buy
- Investors Are Moving into Bonds and Small Cap Stocks: Here’s Why
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
